Spectral Medical Inc. Provides Tigris Clinical Trial Update
Our sites have aggressively increased activities around the Tigris trial, including heightened patient screening, enrollment, and randomization.
- Our sites have aggressively increased activities around the Tigris trial, including heightened patient screening, enrollment, and randomization.
- We are also onboarding additional clinical trial sites, including the University of Michigan, which is now actively screening patients.
- Chris Seto, CEO of Spectral, further noted, With a total of nineteen patients now randomized within the Tigris trial, we are pleased with the acceleration of trial activities and remain optimistic about the trial outcome.
- We remain highly encouraged by the outlook for the Tigris trial based on the outcome of the earlier EUPHRATES trial.